Aug 31, 2008
European agency warns of possible Botox side effects
Aug 31, 2008
The London-based European Medicines Agency had by August 2007 recorded more than 600 cases of negative effects potentially linked to the popular cosmetic treatment, Focus news weekly reported in its issue to be released Monday.
In 28 cases Botox users died.
In Germany the Federal Institute for Medication and Medical Products has received 210 reports with a suspected link to Botox, which is used by millions around the world to iron out wrinkles. Five cases were lethal, Focus said.
Botulinum toxins including Botox are approved in the United States and Europe to treat a variety of conditions including spasms of the eyelids or neck, the easing of facial lines or excessive sweating.
The US Food and Drug Administration (FDA) warned in February that using Botox can have serious side effects including death, but stopped short of banning them.
It stressed at the time that no patients who had used Botox for cosmetic purposes were among the fatalities, but urged vigilance.
The botulinum toxin is a natural poison found in decomposing food that is 40 million times more powerful than cyanide.
When injected, tiny doses paralyse a muscle and prevent it from contracting for between four and six months -- ideal for temporarily eliminating worry lines but potentially deadly if it affects the wrong muscles, authorities said.
Botox and Botox Cosmetic warn on their labels of the possibility of adverse reactions near the site of the injection for each product's approved uses, according to the FDA, and of "the rare potential of distant side effects" including severe difficulty swallowing and breathing when the products are used on patients with neuromuscular disorders.
Copyright © 2022 AFP. All rights reserved. All information displayed in this section (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the contents of this section without the prior written consent of Agence France-Presses.